» Articles » PMID: 27598140

Perillyl Alcohol and Its Drug-Conjugated Derivatives As Potential Novel Methods of Treating Brain Metastases

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2016 Sep 7
PMID 27598140
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis to the central nervous system remains difficult to treat, and such patients are faced with a dismal prognosis. The blood-brain barrier (BBB), despite being partially compromised within malignant lesions in the brain, still retains much of its barrier function and prevents most chemotherapeutic agents from effectively reaching the tumor cells. Here, we review some of the recent developments aimed at overcoming this obstacle in order to more effectively deliver chemotherapeutic agents to the intracranial tumor site. These advances include intranasal delivery to achieve direct nose-to-brain transport of anticancer agents and covalent modification of existing drugs to support enhanced penetration of the BBB. In both of these areas, use of the natural product perillyl alcohol, a monoterpene with anticancer properties, contributed to promising new results, which will be discussed here.

Citing Articles

NEO212, temozolomide conjugated to NEO100, exerts superior therapeutic activity over temozolomide in preclinical chemoradiation models of glioblastoma.

Minea R, Thein T, Yang Z, Campan M, Ward P, Schonthal A Neurooncol Adv. 2024; 6(1):vdae095.

PMID: 39022643 PMC: 11252566. DOI: 10.1093/noajnl/vdae095.


Activation of Epstein-Barr Virus' Lytic Cycle in Nasopharyngeal Carcinoma Cells by NEO212, a Conjugate of Perillyl Alcohol and Temozolomide.

Hartman-Houstman H, Swenson S, Minea R, Sinha U, Chiang M, Chen T Cancers (Basel). 2024; 16(5).

PMID: 38473298 PMC: 10931041. DOI: 10.3390/cancers16050936.


NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity.

Chen T, Minea R, Swenson S, Yang Z, Thein T, Schonthal A Cancers (Basel). 2022; 14(24).

PMID: 36551551 PMC: 9776529. DOI: 10.3390/cancers14246065.


Smart Nanoformulations for Brain Cancer Theranostics: Challenges and Promises.

Ahmad F, Varghese R, Panda S, Ramamoorthy S, Areeshi M, Fagoonee S Cancers (Basel). 2022; 14(21).

PMID: 36358807 PMC: 9655255. DOI: 10.3390/cancers14215389.


Dodging blood brain barrier with "nano" warriors: Novel strategy against ischemic stroke.

Parvez S, Kaushik M, Ali M, Alam M, Ali J, Tabassum H Theranostics. 2022; 12(2):689-719.

PMID: 34976208 PMC: 8692911. DOI: 10.7150/thno.64806.


References
1.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

2.
Demopoulos A . Leptomeningeal metastases. Curr Neurol Neurosci Rep. 2004; 4(3):196-204. DOI: 10.1007/s11910-004-0039-z. View

3.
Chen T, da Fonseca C, Schonthal A . Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy. Am J Cancer Res. 2015; 5(5):1580-93. PMC: 4497427. View

4.
Zhu W, Zhou L, Qian J, Qiu T, Shu Y, Liu P . Temozolomide for treatment of brain metastases: A review of 21 clinical trials. World J Clin Oncol. 2014; 5(1):19-27. PMC: 3920177. DOI: 10.5306/wjco.v5.i1.19. View

5.
Trudeau M, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S . Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol. 2006; 17(6):952-6. DOI: 10.1093/annonc/mdl056. View